GeoVax Seeks Stockholder Approval for Reverse Split and Warrant Exercise to Avoid Nasdaq Delisting
GOVX is trading near its 52-week low of $0.59 (4.9% above the low).
Summary
GeoVax is seeking stockholder approval for a reverse stock split (1-for-10 to 1-for-25) to regain Nasdaq compliance and for issuance of up to 11.4 million shares upon warrant exercise to raise approximately $7.3 million. The special meeting is scheduled for October 27, 2026.
Key Events · Corporate Governance and Compliance · GOVX
-
Reverse Stock Split Proposed
Board seeks authority for a 1-for-10 to 1-for-25 reverse split to regain compliance with Nasdaq's $1.00 minimum bid price rule after receiving a delisting notice on August 27, 2026.
-
Warrant Exercise Approval Sought
Stockholder approval requested for issuance of up to 11,395,256 shares upon exercise of the August 2026 Warrant at $0.64 per share, which would raise approximately $7.3 million in gross proceeds.
-
Nasdaq Delisting Risk
Nasdaq issued a Staff Determination Letter on August 27, 2026, after the stock traded below $1.00 for 30 consecutive business days. Trading suspension is expected September 8, 2026, absent a timely hearing request.
-
Cash Runway Critical
Company had $3.1 million in cash as of the last 10-Q, funding operations only into September 2026. The warrant exercise proceeds are needed to extend the runway.
Analysis · GOVX · Life Sciences
GeoVax is asking stockholders to approve a reverse stock split of 1-for-10 to 1-for-25 to regain compliance with Nasdaq's $1.00 minimum bid price rule after receiving a delisting notice on August 27, 2026. The company also seeks approval to issue up to 11,395,256 shares upon exercise of a warrant issued in an August 25 inducement, which would raise approximately $7.3 million in gross proceeds. With only $3.1 million in cash as of the last 10-Q and operations funded only into September 2026, the reverse split is critical to maintaining Nasdaq listing and the warrant exercise is critical to funding operations. The stock trades at $0.619, near its 52-week low of $0.59, and the company has already completed a 1-for-30 reverse split in January 2026, making this a second reverse split within eight months.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.9% of the 578 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GOVX was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $0.59 to $19.21. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.